BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives

IF 9.6 1区医学 Q1 ONCOLOGY

Cancer treatment reviews Pub Date : 2025-02-20 DOI:10.1016/j.ctrv.2025.102905

Stefania Napolitano , Davide Ciardiello , Eleonora Cioli , Erika Martinelli , Teresa Troiani , Maria Giulia Zampino , Nicola Fazio , Ferdinando De Vita , Fortunato Ciardiello , Giulia Martini

{"title":"BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives","authors":"Stefania Napolitano , Davide Ciardiello , Eleonora Cioli , Erika Martinelli , Teresa Troiani , Maria Giulia Zampino , Nicola Fazio , Ferdinando De Vita , Fortunato Ciardiello , Giulia Martini","doi":"10.1016/j.ctrv.2025.102905","DOIUrl":null,"url":null,"abstract":"<div><div>Detection of the <em>BRAF V600E</em> mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis.</div><div>The evolution of molecular profiling and the implementation of next generation sequencing in the evaluation of a patient with <em>BRAF</em>-mutated mCRC has currently led to the discovery of actionable alterations. Targeting multiple pathways of resistance in <em>BRAF</em>-mutated mCRC may be the most efficacious route. Then, over a short period of time, the treatment landscape <em>BRAF-</em>mutated mCRC patients has shifted dramatically. Finally, novel treatment strategies are available.</div><div>This review will discuss on currently approved treatments for <em>BRAF V600E</em> mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102905"},"PeriodicalIF":9.6000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737225000271","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis.

The evolution of molecular profiling and the implementation of next generation sequencing in the evaluation of a patient with BRAF-mutated mCRC has currently led to the discovery of actionable alterations. Targeting multiple pathways of resistance in BRAF-mutated mCRC may be the most efficacious route. Then, over a short period of time, the treatment landscape BRAF-mutated mCRC patients has shifted dramatically. Finally, novel treatment strategies are available.

This review will discuss on currently approved treatments for BRAF V600E mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy.

查看原文本刊更多论文

BRAFV600E突变转移性结直肠癌：个体化治疗的最新进展及未来展望

BRAF V600E突变的检测对转移性结直肠癌（mCRC）患者具有重要的遗传、预后和治疗意义，确定了从标准治疗中获益有限且预后极差的患者亚组。在对braf突变的mCRC患者进行评估时，分子谱分析的发展和下一代测序的实施目前已经导致了可操作改变的发现。针对braf突变的mCRC的多种耐药途径可能是最有效的途径。然后，在短时间内，braf突变的mCRC患者的治疗前景发生了巨大变化。最后，新的治疗策略是可用的。本综述将讨论目前批准的BRAF V600E突变mCRC的治疗方法，并试图描述在靶向分子治疗时代这一背景下不断变化的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment reviews 医学-肿瘤学

CiteScore

21.40

自引率

0.80%

发文量

109

审稿时长

13 days

期刊介绍： Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews